Christopher Straus

Dr. Christopher Straus

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in Academic Radiology
Verified
Journal Article
Closed access
EWEmily M. Webb
Emily M. Webb
DNDavid M. Naeger
David M. Naeger
TFTracy B. Fulton
Tracy B. Fulton
CSChristopher Straus
Christopher Straus

20 May 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ADArpita Desai
Arpita Desai
TKTheodore Karrison
Theodore Karrison
BRBuerkley Rose
Buerkley Rose
EPErika Pemberton
Erika Pemberton
BHBianca Hill
Bianca Hill
HKHedy L. Kindler
Hedy L. Kindler
8565Background: We conducted a phase II trial (NCT02399371) of P in previously treated MM to characterize activity in a non-selected population and determine a PD-L1 expression threshold Methods: Eligible pts had histologically confirmed MM, PS 0-1, disease progression, 1-2 prior regimens. P 200 mg was given Q21 days; CT scans Q9 weeks. 10 endpoints determine 1) objective response rate (RR) in an unselected and a PD-L1 positive population 2) optimal threshold for PD-L1 expression (22C3 IHC tumor cell/tumor proportion score (TPS) assay). Part A required ≥3 responses in 35 PD-L1 unselected pts. Part B PD-L1 preselects if a threshold is found in Part A. We previously reported (WCLC 2016) 7 responses in Part A; as no PD-L1 threshold was found (ROC 0.62), Part B enrolled 30 pts with no biomarker enrichment. Results: 65 pts enrolled 5/15-2/18; 1 withdrew. Median age: 68 (range 26-85); PS 0: 53%; male: 77%; epithelioid/biphasic/sarcomatoid: 76.6%/15.6%/7.8%; pleural/peritoneal: 87.5%/12.5%; 1 prior regimen: 61%....

26 August 2014 in Physics in Medicine & Biology
Verified
Journal Article
Open access
ACAlexandra R Cunliffe
Alexandra R Cunliffe
SASamuel G Armato
Samuel G Armato
CSChristopher Straus
Christopher Straus
RMRenuka Malik
Renuka Malik
HAHania A Al-Hallaq
Hania A Al-Hallaq
This study examines the correlation between the radiologist-defined severity of normal tissue damage following radiation therapy (RT) for lung cancer treatment and a set of mathematical descriptors of computed tomography (CT) scan texture ('texture features'). A pre-therapy CT scan and a post-therapy CT scan were retrospectively collected under IRB approval for each of the 25 patients who underwent definitive RT (median dose: 66 Gy). Sixty regions of interest (ROIs) were automatically identified in the non-cancerous lung tissue of each post-therapy scan. A radiologist compared post-therapy scan ROIs with pre-therapy scans and categorized each as containing no abnormality, mild abnormality, moderate abnormality, or severe abnormality. Twenty texture features that characterize gray-level intensity, region morphology, and gray-level distribution were calculated in post-therapy scan ROIs and compared with anatomically matched ROIs in the pre-therapy scan. Linear regression and receiver operating characteristic (ROC) analysis were used to compare the percent feature value change (ΔFV) between ROIs at each category of visible radiation damage. Most ROIs contained no (65%) or mild abnormality (30%). ROIs with moderate (3%) or severe (2%) abnormalities were observed in 9 patients. For 19 of 20 features, ΔFV was significantly different among severity levels. For 12 features, significant differences were observed at every level. Compared with regions with no abnormalities, ΔFV for these 12 features increased, on average, by 1.5%, 12%, and 30%, respectively, for mild, moderate, and severe abnormalitites. Area under the ROC curve was largest when comparing ΔFV in the highest severity level with the remaining three categories (mean AUC across features: 0.84). In conclusion, 19 features that characterized the severity of radiologic changes from pre-therapy scans were identified. These features may be used in future studies to quantify acute normal lung tissue damage following RT.

13 June 2017 in Anatomical Sciences Education
Verified
Journal Article
Closed access
PDF file
APAndrew W. Phillips
Andrew W. Phillips
HEHunter Eason
Hunter Eason
CSChristopher Straus
Christopher Straus

1 January 2020 in Journal of Medical Imaging
Verified
Journal Article
Closed access
PDF file
EGEyjólfur Gudmundsson
Eyjólfur Gudmundsson
CSChristopher Straus
Christopher Straus
FLFeng Li
Feng Li
SASamuel G. Armato
Samuel G. Armato
Tumor volume is a topic of interest for the prognostic assessment, treatment response evaluation, and staging of malignant pleural mesothelioma. Many mesothelioma patients present with, or develop, pleural fluid, which may complicate the segmentation of this disease. Deep convolutional neural networks (CNNs) of the two-dimensional U-Net architecture were trained for segmentation of tumor in the left and right hemithoraces, with the networks initialized through layers pretrained on ImageNet. Networks were trained on a dataset of 5230 axial sections from 154 CT scans of 126 mesothelioma patients. A test set of 94 CT sections from 34 patients, who all presented with both tumor and pleural effusion, in addition to a more general test set of 130 CT sections from 43 patients, were used to evaluate segmentation performance of the deep CNNs. The Dice similarity coefficient (DSC), average Hausdorff distance, and bias in predicted tumor area were calculated through comparisons with radiologist-provided tumor segmentations on the test sets. The present method achieved a median DSC of 0.690 on the tumor and effusion test set and achieved significantly higher performance on both test sets when compared with a previous deep learning-based segmentation method for mesothelioma.

19 November 2022 in Academic Radiology
Verified
Journal Article
Closed access
SFShannon G. Farmakis
Shannon G. Farmakis
JCJocelyn D. Chertoff
Jocelyn D. Chertoff
CSChristopher Straus
Christopher Straus
RBRichard A. Barth
Richard A. Barth